BioStem Technologies Completes Enrollment in Clinical Trial
BioStem Technologies, Inc. (OTC: BSEM), a prominent name in MedTech, has successfully concluded patient enrollment for its pivotal clinical trial targeting diabetic foot ulcers (DFUs). This trial is focused on comparing the efficiency of the BioREtain® Amnion Chorion (BR-AC) allograft against the conventional standard care methods. The study promises not only to shine a light on healing efficacy but also to establish a new standard in advanced wound care treatments.
The Importance of the Clinical Trial
Conducted across various centers, the BR-AC-DFU-101 study aims to evaluate at least 60 patients suffering from non-healing DFUs. The main goal is to understand if the combination of standard care and BR-AC yields a higher chance of complete wound healing within a 12-week timeframe, when juxtaposed against the standard care alone. This trial, initiated in late 2024, has already seen an impressive enrollment of 71 patients, with results anticipated in the upcoming fourth quarter of 2025.
CEO Insights on the Trial Progress
“Advancing the clinical trials is crucial for us,” stated Jason Matuszewski, CEO and Chairman of BioStem Technologies. “I am pleased with the progress of our ongoing trials and the completed enrollment marks a significant milestone for us. As we work on additional studies targeting other types of ulcers, we remain committed to generating robust clinical data that validates our BioREtain® platform.”
Objectives and Expected Outcomes of the Trial
The clinical trial has been designed with clear primary and secondary outcome objectives. The primary objective is to establish whether treatment involving BR-AC enhances the likelihood of complete wound closure compared to standard treatment alone over the specified period.
Secondary Measures Being Analyzed
Alongside the primary outcomes, several secondary measures will also be assessed. These include:
- Differences in the rates of complete wound closure correlated with time.
- Comparing variations in wound area and volume between treatment groups.
- The required number of BR-AC applications to achieve full healing.
The Seriousness of Diabetic Foot Ulcers
Diabetic foot ulcers pose a severe health risk, impacting millions globally. Approximately 15% of individuals with diabetes experience foot ulcers, and alarmingly, a significant portion may face hospitalization due to complications. These ulcers are recognized as a leading cause of amputations in individuals with diabetes, with research indicating that up to 24% of affected individuals may eventually require such drastic measures.
Market Statistics and Economic Impact
Recent analyses indicate that around 2.2 million patients sought treatment for DFUs, with costs escalating between $9 billion and $13 billion annually in the United States alone. These figures underscore the urgent need for effective treatment options within the healthcare system to mitigate both the financial strain and health implications associated with DFUs.
About BioREtain®
BioStem’s innovative approach incorporates the proprietary BioREtain® processing method, which expertly preserves the intrinsic qualities of the perinatal tissue. This meticulous process ensures that the allografts maintain their structural integrity and natural components vital for effective wound healing, offering hope for patients battling chronic wounds.
About BioStem Technologies, Inc.
BioStem Technologies, Inc. focuses on creating advanced allografts aimed at changing lives through effective wound care. With their products adhering to stringent quality standards, their team is determined to improve patient outcomes and expand the understanding and adoption of their technologies in the medical community.
Frequently Asked Questions
What is BioStem Technologies working on currently?
BioStem is advancing multiple clinical trials to evaluate the efficacy of their BioREtain® technology in treating various types of wounds, including diabetic foot ulcers.
When are results expected from the current trial?
The company anticipates reporting topline trial results in the fourth quarter of 2025.
What is the focus of the BR-AC-DFU-101 study?
This multicenter trial focuses on assessing the effectiveness of BR-AC plus standard care in achieving wound healing among diabetic foot ulcer patients.
Why is diabetic foot ulcer treatment crucial?
DFUs can lead to severe complications, including hospitalization and amputations, making effective treatment critical for diabetic patients.
How is BioREtain® different from standard treatment methods?
BioREtain® processing preserves the natural properties of perinatal tissue, offering a potentially superior option for wound healing compared to traditional methods.
